Dat bericht van 22 oktober :huh:
Ik heb nu 6.5 jaar tysabri en denk echt te merken dat ik het laatste jaar steeds vermoeider wordt aan het einde van de 4 weken, dit heb ik ook met de neuroloog besproken en hij zei dat meer patiënten dit melden. :???:
Veiligheid van Tysabri
-
Marsei
Conversion to JCV Positivity Common With Natalizumab in MS
Conversion to JCV Positivity Common With Natalizumab in MS
[URL="http://www.medscape.com/viewarticle/852 ... 179CY#vp_1"][U]Conversion to JCV Positivity[/U][/URL] Common With Natalizumab in MS
[QUOTE]Nearly a quarter of patients with multiple sclerosis (MS) being treated with natalizumab (Tysabri, Biogen Idec) convert from a negative status of JC virus (JCV) antibodies to positive, but factors such as duration of natalizumab treatment do not appear to affect JCV antibody levels — or conversion to progressive multifocal leukoencephalopathy (PML) — a longitudinal study suggests.[/QUOTE]
[URL="http://www.medscape.com/viewarticle/852 ... 179CY#vp_1"][U]Conversion to JCV Positivity[/U][/URL] Common With Natalizumab in MS
[QUOTE]Nearly a quarter of patients with multiple sclerosis (MS) being treated with natalizumab (Tysabri, Biogen Idec) convert from a negative status of JC virus (JCV) antibodies to positive, but factors such as duration of natalizumab treatment do not appear to affect JCV antibody levels — or conversion to progressive multifocal leukoencephalopathy (PML) — a longitudinal study suggests.[/QUOTE]
-
Marsei
PML ondanks negatief JCV test resultaat
PML ondanks negatief JCV test resultaat
[URL="http://www.medscape.com/viewarticle/857 ... c=168179CY"][U]PML[/U][/URL] With Natalizumab Despite Recent Negative JCV Test Result
[QUOTE]A case of progressive multifocal leukoencephalopathy (PML) associated with natalizumab (Tysabri, Biogen) therapy has been reported in a patient with multiple sclerosis (MS) who had tested negative for JC virus (JCV) antibodies just 2 weeks before symptoms developed.[/QUOTE]
[QUOTE]"This case exemplifies the risk of delay in PML diagnosis for initial misdiagnosis of MS exacerbation, reiterating that a natalizumab-treated patient with any new MRI lesion or neurologic symptoms could have PML, independent of JCV antibody status," they conclude. "Short-term clinical and MRI reassessment, repeat anti-JCV antibody testing, and CSF [cerebrospinal fluid] testing may be warranted, depending on the level of clinical suspicion."
Commenting on the case for Medscape Medical News, Jeffrey Cohen, MD, Cleveland Clinic, Ohio, said this case illustrates two important points.
"First, although negative JCV serology is reassuring and lessens the risk of PML, there is a low but finite false-negative rate," he said. "Second, any new MRI lesion or apparent relapse in a patient on Tysabri is suspicious, particularly with prolonged treatment."
The authors note that as of March 2015, Biogen had reported 541 cases of natalizumab-related PML. Of 278 cases with available data, only 2 were negative for anti-JCV antibodies and these patients had tests dating from 8 and 9 months before diagnosis.
"The notable finding in this patient is the 2-week timespan between the most recent negative anti-JCV antibody test result and the onset of PML symptoms," they write.
The patient in this case, a 70-year-old woman with MS, had been taking natalizumab since January 2010, had never received immunosuppressants, and had had several negative JCV antibody test results, the most recent of which was just 2 weeks before the onset of PML symptoms.[/QUOTE]
[QUOTE]The researchers note that patients with negative JCV antibody results are still at risk for PML because of the potential for de novo infection as well as the possibility of false-negative test results, which may be as high as 3%.[/QUOTE]
[URL="http://www.medscape.com/viewarticle/857 ... c=168179CY"][U]PML[/U][/URL] With Natalizumab Despite Recent Negative JCV Test Result
[QUOTE]A case of progressive multifocal leukoencephalopathy (PML) associated with natalizumab (Tysabri, Biogen) therapy has been reported in a patient with multiple sclerosis (MS) who had tested negative for JC virus (JCV) antibodies just 2 weeks before symptoms developed.[/QUOTE]
[QUOTE]"This case exemplifies the risk of delay in PML diagnosis for initial misdiagnosis of MS exacerbation, reiterating that a natalizumab-treated patient with any new MRI lesion or neurologic symptoms could have PML, independent of JCV antibody status," they conclude. "Short-term clinical and MRI reassessment, repeat anti-JCV antibody testing, and CSF [cerebrospinal fluid] testing may be warranted, depending on the level of clinical suspicion."
Commenting on the case for Medscape Medical News, Jeffrey Cohen, MD, Cleveland Clinic, Ohio, said this case illustrates two important points.
"First, although negative JCV serology is reassuring and lessens the risk of PML, there is a low but finite false-negative rate," he said. "Second, any new MRI lesion or apparent relapse in a patient on Tysabri is suspicious, particularly with prolonged treatment."
The authors note that as of March 2015, Biogen had reported 541 cases of natalizumab-related PML. Of 278 cases with available data, only 2 were negative for anti-JCV antibodies and these patients had tests dating from 8 and 9 months before diagnosis.
"The notable finding in this patient is the 2-week timespan between the most recent negative anti-JCV antibody test result and the onset of PML symptoms," they write.
The patient in this case, a 70-year-old woman with MS, had been taking natalizumab since January 2010, had never received immunosuppressants, and had had several negative JCV antibody test results, the most recent of which was just 2 weeks before the onset of PML symptoms.[/QUOTE]
[QUOTE]The researchers note that patients with negative JCV antibody results are still at risk for PML because of the potential for de novo infection as well as the possibility of false-negative test results, which may be as high as 3%.[/QUOTE]
-
Marsei
Therapy with tysabri is associated with high JCV seroconversion and rising JCV values
Therapy with tysabri is associated with high JCV seroconversion and rising JCV values
Therapy with natalizumab is associated with [URL="http://nn.neurology.org/content/3/1/e195.full"][U]high JCV seroconversion [/U][/URL]and rising JCV index values
Van Joan: [QUOTE]New Research: Tysabri usage changes status in patients from JC- to JC+ This "seroconversion" happened in over 10% of people on Tysabri. Please read and share this study. Bottom line---using Tysabri has a ten time higher risk of seroconversion to JC+ and potential PML than thought previously. [/QUOTE]
[QUOTE][B]ABSTRACT[/B]
[B]Objective[/B]: The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment.
[B]Methods[/B]: German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were assessed for JCV serology alongside their therapy with natalizumab.
[B]Results[/B]: JCV serostatus changed in 69 of 525 longitudinally followed German patients (13.1%) over 14.8 months. Seroconversion according to serostatus was seen in 43 of 339 initially JCV− German patients (12.7% in 14.8 months; 10.3% per year) and 41 of 243 initially JCV− French patients (16.9% in 24 months; 8.5% per year).
JCV index values could be reproduced (R2 = 0.89) with the caveat of 8 of 50 samples (16%) being set into different risk categories between 2 assessments. Index values of JCV+ patients rose over time (p = 0.009) but not because of aging. Treatment with natalizumab was associated with a 15.9% increase of value in JCV+ patients in 14.8 months (12.9% per year).
[B]Conclusions[/B]: JCV seroconversion and index values may be influenced by treatment with natalizumab. It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification.[/QUOTE]
Therapy with natalizumab is associated with [URL="http://nn.neurology.org/content/3/1/e195.full"][U]high JCV seroconversion [/U][/URL]and rising JCV index values
Van Joan: [QUOTE]New Research: Tysabri usage changes status in patients from JC- to JC+ This "seroconversion" happened in over 10% of people on Tysabri. Please read and share this study. Bottom line---using Tysabri has a ten time higher risk of seroconversion to JC+ and potential PML than thought previously. [/QUOTE]
[QUOTE][B]ABSTRACT[/B]
[B]Objective[/B]: The aim of the study was to analyze John Cunningham virus (JCV) serology in natalizumab-treated patients over time and assess whether they are influenced by natalizumab treatment.
[B]Methods[/B]: German (n = 1,921; 525 longitudinally) and French (n = 1,259; 711 longitudinally) patients were assessed for JCV serology alongside their therapy with natalizumab.
[B]Results[/B]: JCV serostatus changed in 69 of 525 longitudinally followed German patients (13.1%) over 14.8 months. Seroconversion according to serostatus was seen in 43 of 339 initially JCV− German patients (12.7% in 14.8 months; 10.3% per year) and 41 of 243 initially JCV− French patients (16.9% in 24 months; 8.5% per year).
JCV index values could be reproduced (R2 = 0.89) with the caveat of 8 of 50 samples (16%) being set into different risk categories between 2 assessments. Index values of JCV+ patients rose over time (p = 0.009) but not because of aging. Treatment with natalizumab was associated with a 15.9% increase of value in JCV+ patients in 14.8 months (12.9% per year).
[B]Conclusions[/B]: JCV seroconversion and index values may be influenced by treatment with natalizumab. It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification.[/QUOTE]
-
Marsei
De weg naar geïndividualiseerde MS-zorg
De weg naar geïndividualiseerde MS-zorg
De weg naar [URL="https://www.msweb.nl/ms-onderzoek/proef ... talizumab/"][U]geïndividualiseerde MS-zorg
[/U][/URL]
[QUOTE][B]Door het meten van de concentratie van de stof natalizumab in het bloed bij mensen met MS kan een geïndividualiseerd behandelplan voor dit MS-medicijn opgesteld worden.
[/B]
[I]Promotie: Anke Vennegoor, 30 juni 2017 VUmc.
[/I]
In de afgelopen jaren zijn meerdere medicijnen voor MS op de markt gekomen en er zijn er nog een aantal onderweg. Natalizumab is een van de meest effectieve therapieën. Helaas geeft dit een uiterst zeldzame, maar potentieel dodelijke aandoening als mogelijke bijwerking, namelijk progressieve multifocale leukoencephalopathie (PML), veroorzaakt door het John Cunningham (JC)-virus.
[B]Spiegel[/B]
Anke Vennegoor heeft in haar promotieonderzoek gekeken naar de effectiviteit van de behandeling met natalizumab en de belangrijkste risicofactoren op PML. Eén van haar bevindingen is dat het meten van de concentratie natalizumab in het bloed (natalizumab spiegel) net zo geschikt is als het meten van anti-natalizumab antistoffen ter beoordeling van de effectiviteit van natalizumab. Het grote voordeel is dat het meten van de natalizumab spiegels eenvoudiger is en dat het kan leiden tot een meer geïndividualiseerde behandeling van mensen met MS. Dit kan door de hoeveelheid natalizumab-infusen per jaar aan te passen aan de natalizumab spiegel. Daarnaast kan het meten van de natalizumab spiegel gebruikt worden op het moment dat PML zich ontwikkeld heeft en het belangrijk is dat de natalizumab snel en volledig uit het lichaam verdwijnt.
[B]John Cunningham-virus[/B]
Ongeveer de helft van de bevolking draagt het JC-virus bij zich (JCV-positief). Een tweede belangrijke bevinding van Vennegoor is dat mensen met MS die met natalizumab behandeld worden een groter risico lopen om JCV-positief te worden, dan tot nu toe beschreven is in de literatuur in de algemene populatie. Dit verhoogde risico moet meegewogen worden als je besluit te starten met natalizumab.
[B]Vervolg[/B]
In een vervolgonderzoek dat momenteel bij VUmc wordt uitgevoerd, krijgen deelnemers pas een volgende dosis natalizumab als de spiegel in het bloed voldoende gedaald is. Dit kan leiden tot aanzienlijk minder ziekenhuisbezoeken en een forse afname in kosten van het medicijngebruik.[/QUOTE]
De weg naar [URL="https://www.msweb.nl/ms-onderzoek/proef ... talizumab/"][U]geïndividualiseerde MS-zorg
[/U][/URL]
[QUOTE][B]Door het meten van de concentratie van de stof natalizumab in het bloed bij mensen met MS kan een geïndividualiseerd behandelplan voor dit MS-medicijn opgesteld worden.
[/B]
[I]Promotie: Anke Vennegoor, 30 juni 2017 VUmc.
[/I]
In de afgelopen jaren zijn meerdere medicijnen voor MS op de markt gekomen en er zijn er nog een aantal onderweg. Natalizumab is een van de meest effectieve therapieën. Helaas geeft dit een uiterst zeldzame, maar potentieel dodelijke aandoening als mogelijke bijwerking, namelijk progressieve multifocale leukoencephalopathie (PML), veroorzaakt door het John Cunningham (JC)-virus.
[B]Spiegel[/B]
Anke Vennegoor heeft in haar promotieonderzoek gekeken naar de effectiviteit van de behandeling met natalizumab en de belangrijkste risicofactoren op PML. Eén van haar bevindingen is dat het meten van de concentratie natalizumab in het bloed (natalizumab spiegel) net zo geschikt is als het meten van anti-natalizumab antistoffen ter beoordeling van de effectiviteit van natalizumab. Het grote voordeel is dat het meten van de natalizumab spiegels eenvoudiger is en dat het kan leiden tot een meer geïndividualiseerde behandeling van mensen met MS. Dit kan door de hoeveelheid natalizumab-infusen per jaar aan te passen aan de natalizumab spiegel. Daarnaast kan het meten van de natalizumab spiegel gebruikt worden op het moment dat PML zich ontwikkeld heeft en het belangrijk is dat de natalizumab snel en volledig uit het lichaam verdwijnt.
[B]John Cunningham-virus[/B]
Ongeveer de helft van de bevolking draagt het JC-virus bij zich (JCV-positief). Een tweede belangrijke bevinding van Vennegoor is dat mensen met MS die met natalizumab behandeld worden een groter risico lopen om JCV-positief te worden, dan tot nu toe beschreven is in de literatuur in de algemene populatie. Dit verhoogde risico moet meegewogen worden als je besluit te starten met natalizumab.
[B]Vervolg[/B]
In een vervolgonderzoek dat momenteel bij VUmc wordt uitgevoerd, krijgen deelnemers pas een volgende dosis natalizumab als de spiegel in het bloed voldoende gedaald is. Dit kan leiden tot aanzienlijk minder ziekenhuisbezoeken en een forse afname in kosten van het medicijngebruik.[/QUOTE]
-
Marsei
Link Between MS Therapy Tysabri and Melanoma Possible
Link Between MS Therapy Tysabri and Melanoma Possible
Link Between MS Therapy Tysabri and [URL="https://multiplesclerosisnewstoday.com/ ... -melanoma/"][U]Melanoma[/U][/URL] Possible, an Adverse Reactions Watchdog Group Says
[QUOTE]The multiple sclerosis therapy Tysabri (natalizumab) could trigger melanoma, the Southern Network on Adverse Reactions (SONAR) has warned.
Although its investigation failed to demonstrate that melanoma is more common among Tysabri-treated MS patients than in the general population, unusual features among the patients raise concerns about a possible link, the organization said.[/QUOTE]
[QUOTE]To minimize the risk of patients who receive Tysabri developing melanoma, the researchers offered a number of suggestions for IV centers, physicians, patients, and educational programs. For instance, they suggested that all patients should have a skin examination before the start of treatment, and regular physical and skin exams while receiving Tysabri.
While noting that risk of infection and the development of tumors can occur with all immunosuppressive treatments, the team said more studies are needed to explore the risk of Tysabri-treated patients developing melanoma.[/QUOTE]
Link Between MS Therapy Tysabri and [URL="https://multiplesclerosisnewstoday.com/ ... -melanoma/"][U]Melanoma[/U][/URL] Possible, an Adverse Reactions Watchdog Group Says
[QUOTE]The multiple sclerosis therapy Tysabri (natalizumab) could trigger melanoma, the Southern Network on Adverse Reactions (SONAR) has warned.
Although its investigation failed to demonstrate that melanoma is more common among Tysabri-treated MS patients than in the general population, unusual features among the patients raise concerns about a possible link, the organization said.[/QUOTE]
[QUOTE]To minimize the risk of patients who receive Tysabri developing melanoma, the researchers offered a number of suggestions for IV centers, physicians, patients, and educational programs. For instance, they suggested that all patients should have a skin examination before the start of treatment, and regular physical and skin exams while receiving Tysabri.
While noting that risk of infection and the development of tumors can occur with all immunosuppressive treatments, the team said more studies are needed to explore the risk of Tysabri-treated patients developing melanoma.[/QUOTE]
-
greyde
Ik krijg vandaag dit bericht binnen.
Heeft wel heel lang geduurd voor ze eindelijk echt aan de gang gaan met dit onderzoek.
[url]https://www.skipr.nl/actueel/id38724-kw ... eling.html[/url]
Deel je ervaringen over dit onderwerp op MS.nl.
Ga naar: https://www.ms.nl/gesprekken/medicatie-en-bijwerkingen
Heeft wel heel lang geduurd voor ze eindelijk echt aan de gang gaan met dit onderzoek.
[url]https://www.skipr.nl/actueel/id38724-kw ... eling.html[/url]
Deel je ervaringen over dit onderwerp op MS.nl.
Ga naar: https://www.ms.nl/gesprekken/medicatie-en-bijwerkingen